A5024258790- Clostridium difficile and Clostridium perfringens research
- Microscopic Colitis
- Gut microbiota and health
- Nosocomial Infections in ICU
- Helicobacter pylori-related gastroenterology studies
- Bacterial Identification and Susceptibility Testing
- Gastrointestinal motility and disorders
- Antimicrobial Resistance in Staphylococcus
- Antibiotic Resistance in Bacteria
- Antibiotics Pharmacokinetics and Efficacy
- Neutropenia and Cancer Infections
- Diet and metabolism studies
- Viral gastroenteritis research and epidemiology
- Mycobacterium research and diagnosis
- Streptococcal Infections and Treatments
- Sepsis Diagnosis and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Bacterial biofilms and quorum sensing
- Respiratory and Cough-Related Research
- Antibiotic Use and Resistance
- Pneumonia and Respiratory Infections
- Infection Control in Healthcare
- Healthcare cost, quality, practices
- SARS-CoV-2 detection and testing
- Infection Control and Ventilation
University of Calgary
2016-2025
Foothills Medical Centre
2006-2024
Oregon Medical Research Center
2024
University of Pittsburgh
2024
Communities In Schools of Orange County
2024
New York Proton Center
2024
Lindsay Unified School District
2024
Alberta Health Services
2013-2023
University of Chicago
2021
Science Research Laboratory
2019
Clostridium difficile infection is a serious diarrheal illness associated with substantial morbidity and mortality. Patients generally have response to oral vancomycin or metronidazole; however, the rate of recurrence high. This phase 3 clinical trial compared efficacy safety fidaxomicin those in treating C. infection.Adults acute symptoms positive result on stool toxin test were eligible for study entry. We randomly assigned patients receive (200 mg twice daily) (125 four times orally 10...
ABSTRACT Staphylococcal cassette chromosome mec (SCC ) typing is essential for understanding the molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA). SCC elements are currently classified into types I to V based on nature and ccr gene complexes, further subtypes according their junkyard region DNA segments. Previously described traditional PCR schemes require multiple primer sets experiments, while a previously published multiplex assay limited in its ability detect...
<h3>Importance</h3> Fecal microbiota transplantation (FMT) is effective in preventing recurrent<i>Clostridium difficile</i>infection (RCDI). However, it not known whether clinical efficacy differs by route of delivery. <h3>Objective</h3> To determine FMT oral capsule noninferior to colonoscopy delivery efficacy. <h3>Design, Setting, and Participants</h3> Noninferiority, unblinded, randomized trial conducted 3 academic centers Alberta, Canada. A total 116 adult patients with RCDI were...
Understanding gut microbiome functions requires cultivated bacteria for experimental validation and reference bacterial genome sequences to interpret metagenome datasets guide functional analyses. We present the Human Gastrointestinal Bacteria Culture Collection (HBC), a comprehensive set of 737 whole-genome-sequenced isolates, representing 273 species (105 novel species) from 31 families found in human gastrointestinal microbiota. The HBC increases number genomes derived microbiota by 37%....
Background. Clostridium difficile infection (CDI) is a common complication of antibiotic therapy that treated with antibiotics, contributing to ongoing disruption the colonic microbiota and CDI recurrence. Two multinational trials were conducted compare efficacy tolevamer, nonantibiotic, toxin-binding polymer, vancomycin metronidazole. Methods. Patients randomly assigned in 2:1:1 ratio oral tolevamer 9 g (loading dose) followed by 3 every 8 hours for 14 days, 125 mg 6 10 or metronidazole 375...
Intra-abdominal sepsis was studied in Wistar rats by using four microbial species: Escherichia coli, enterococci, Bacteroides fragilis, and Fusobacterium varium. These organisms were implanted into the peritoneal cavity singly all possible dual combinations. Results evaluated mortality rates incidence of intra-abdominal abscesses on autopsy following sacrifice after 7 days. Mortality restricted to recipients E. thus implicating coliforms acute lethality associated with this experimental...
ABSTRACT We developed a new multiplex PCR assay for detection of Panton-Valentine leukocidin virulence genes and simultaneous discrimination methicillin-susceptible from -resistant staphylococci. This is simple, rapid, accurate offers the potential prompt newly emerging community-associated methicillin-resistant Staphylococcus aureus .
Recurrence of Clostridium difficile infection (CDI) occurs in approximately 25% successfully treated patients. Two phase 3 randomized, double-blind trials were conducted at 154 sites the United States, Canada, and Europe to compare fidaxomicin vs vancomycin treating CDI. Patients with CDI received 200 mg twice daily or 125 4 times for 10 days. The primary end point was clinical cure treatment, a secondary recurrence during 28 days following cure. In all, 1164 subjects enrolled, which...
The microflora-sparing properties of fidaxomicin were examined during the conduct a randomized clinical trial comparing vancomycin 125 mg 4 times per day versus 200 twice for 10 days as treatment Clostridium difficile infection (CDI). Fecal samples obtained from 89 patients (45 received fidaxomicin, and 44 vancomycin) at study entry on 4, 10, 14, 21, 28, 38 quantitative cultures C. cytotoxin B fecal filtrate concentrations. Additionally, patients, each receiving or healthy controls analyzed...
Background. Treatment guidelines recommend stopping all implicated antibiotics at the onset of Clostridium difficile infection (CDI), but many individuals have persistent or new infections necessitating use concomitant (CAs). We used data from 2 phase 3 trials to study effects CAs on response fidaxomicin vancomycin. Methods. Subjects with CDI were treated for 10 days 200 mg every 12 hours vancomycin 125 6 hours, assessed resolution symptoms, and followed up an additional 4 weeks evidence...
Recurrent Clostridioides difficile infection, associated with dysbiosis of gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic product consisting broad consortium microbes prepared from human stool that under investigation for reduction recurrent C. infection. A randomized, double-blind, placebo-controlled, phase III study, Bayesian primary analysis integrating data previous IIb was conducted. Adults who had one or more infection recurrences positive...
Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. spore germination into toxin-producing bacteria. SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores treatment infection.We conducted a phase 3, double-blind, randomized, placebo-controlled trial in patients who had three or more episodes (inclusive qualifying acute episode) received placebo (four capsules daily 3 days) after...
The effect of rationally defined nonpathogenic, nontoxigenic, commensal strains Clostridia on prevention Clostridioides difficile infection (CDI) is unknown.To determine the efficacy VE303, a bacterial consortium 8 Clostridia, in adults at high risk for CDI recurrence. primary objective was to recommended VE303 dosing phase 3 trial.Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from February 2019 September 2021 27 sites US and Canada. included 79...
Changes in microbial community composition as a function of human health and disease states have sparked remarkable interest the gut microbiome. However, establishing reproducible insights into determinants succession has been formidable challenge.
Importance A safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted microbiome, which promotes spore germination recurrence. Objectives To evaluate safety rate of CDI recurrence after administration investigational microbiome therapeutic SER-109 through 24 weeks. Design, Setting, Participants This phase 3, single-arm, open-label trial (ECOSPOR IV) was conducted at 72 US...
Microbiota-based treatments reduce the incidence of recurrent Clostridioides difficile infections (rCDIs), but prospectively collected safety data needed to broaden patient access and protect public health have been limited.We provide cumulative from five prospective clinical trials evaluating fecal microbiota, live-jslm (RBL) - first microbiota-based live biotherapeutic product approved by US Food Drug Administration for preventing rCDI in adults.Integrated analysis includes three phase II...
ABSTRACT Major challenges in diagnostic molecular microbiology are to develop a simple assay distinguish Staphylococcus aureus from the less virulent but clinically important coagulase-negative staphylococci (CoNS) and simultaneously determine their antibiotic resistance profiles. Multiplex PCR assays have been developed for detection of methicillin- mupirocin-resistant S. CoNS not simultaneous discrimination CoNS. We designed new set genus-specific primers novel quadriplex targeting 16S...
Septic complications of colonic perforation involve multiple bacteria derived from the intestinal flora. This type mixed intraabdominal infection was produced experimentally by insertion a standardized inoculum rat contents into peritoneal cavity male Wistar rats. The respective roles coliforms and anaerobic were then studied use selective antimicrobial therapy (with gentamicin c1indamycin). Untreated rats had two-stage disease. Initially, there an acute peritonitis associated with 37%...
Twenty diabetic foot ulcers were cultured using optimal microbiologic techniques. Anaerobic bacteria coexisted with the more commonly recognized aerobic in 18 specimens. There a total of 116 isolates an average 5.8 species per specimen (3.2 aerobes and 2.6 anaerobes). The principal Bacteroides (sp.) (17 strains), peptococci (16), Proteus sp. (11), enterococci (9), Staphylococcus aureus (7), clostridia Escherichia coli (6). When antimicrobial therapy is indicated selection agents should...
Clostridium difficile infection (CDI) is the most common identifiable cause of diarrhoea in hospitalized patients. Current therapies rely on administration metronidazole or vancomycin, which reduce vegetative populations C. bowel. Recurrence disease when treatment with these antibiotics ceases indicates that and vancomycin affect not only but also commensal normally mediate competitive exclusion. Fidaxomicin a new antibiotic inhibits difficile. Our study shows fidaxomicin had little effect...
Current antibiotic therapies for Clostridium difficile-associated diarrhea have limitations, including progression to severe disease, recurrent C. diarrhea, and selection nosocomial pathogens. Tolevamer, a soluble, high-molecular weight, anionic polymer that binds difficile toxins A B is unique nonantibiotic treatment option.In this 3-arm, multicenter, randomized, double-blind, active-controlled, parallel-design phase II study, patients with mild moderately were randomized receive 3 g of...